This operation enables Almirall to complement its commitment to innovation through pharmacogenetics and personalised medicine, one of the specialist areas of AB-Biotics.
Almirall becoming part of the share capital of AB-Biotics will enhance the commercial expansion of the pharmacogenetics tests developed by the biotech company. Both companies will be working together on the promotion and commercialisation of Neurofarmagen in Spain from 2013.
Source: Almirall
© FoodBev Media Ltd 2024